Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jul 13, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
43.4%
-27.8% vs 52w high · +15.6% 1mo
Price (last ~year)
Novo Nordisk (NVO) posted 24.0% year-over-year revenue growth and a 67.1% increase in earnings, reporting $96.82 billion in revenue and $48.56 billion in net income for the quarter ending March 31, 2026. The company maintains a 61.6% operating margin and a market capitalization of $218.94 billion, trading at a P/E of 11.87. Recent operational developments include the launch of a once-a-week insulin in India and a collaboration on a semaglutide implant, alongside the withdrawal of a study for its CagriSema device.
Valuation
- Market cap
- $218.94B
- P/E
- 11.87
- PEG
- 3.658
- P/B
- 7.09
- P/S
- 0.668
- EV/EBITDA
- 8.62
- Beta
- 0.36
- Analyst target
- $47.95
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $49.48
- 1-month
- +15.6%
- 3-month
- +25.8%
- RSI (14)
- 79
- vs SMA200
- +6.4%
- 52-wk position
- 43.4% -27.8% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Somewhat-Bullish Weight-loss implant could one day replace Ozempic injections · 2026-07-12
- Somewhat-Bearish Novo Nordisk’s Hemophilia Drug Delivers Strong Results, but Analysts See 10% Downside for NVO Stock · 2026-07-12
- Bullish No easy answers: European research consortia take on major challenges · 2026-07-10
- Somewhat-Bearish Novo Nordisk Withdraws CagriSema Device Study, Nudging Investor Focus Back to Core Obesity Assets · 2026-07-09
- Somewhat-Bullish Novo Nordisk asks public to ‘Meet Me in the Middle’ in new obesity experience installation · 2026-07-09
- Neutral India gets world's first once-a-week insulin: All about Novo Nordisk's Awiqli · 2026-07-09
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)